Macular cystoid spaces in patients with retinal dystrophy

Michelle D. Lingao, Anuradha Ganesh, Arcot S. Karthikeyan, Sana Al Zuhaibi, Amna Al-Hosni, Aisha Al Khayat, Jenina Capasso, Anya A. Trumler, Eliza Stroh, Hilal Al Shekaili, Jacqueline R. Cater, Alex V. Levin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Non leaking macular cystoid spaces (MCS) are seen in some retinal dystrophies. Carbonic anhydrase inhibitor (CAI) treatment may reduce the size of MSC and improve vision. Methods: A retrospective study of patients with retinal dystrophy with MCS seen between 2009 and 2013 at two sites. Patients had ophthalmic examination, optical coherence tomography (OCT) and genetic testing. Patients with vision worse than 20/30 were treated with CAI. Post treatment visual acuity (VA), central foveal zone (CFZ) thickness, and qualitative estimation of MCS size were assessed. Results: Eighteen patients, 6–47 years old, were included. IVFA was performed in 15 (83%) patients. Of the 26 eyes in 13 patients who were treated and followed, VA improved in 15 eyes (58%) of 10 patients. Ten of these 15 eyes had decreased CFZ thickness and 9/10 showed qualitative MCS improvement. Regression analysis showed that change in CFZ thickness was not significantly predictive of change in final visual acuity (p = 0.405). Five of 15 eyes with improved VA had paradoxically increased CFZ thickness and 2/5 had enlarged MCS. Three of the treated eyes (11%) in two patients had decreased VA with decreased CFZ thickness and improved MCS in 2/3 eyes. Eight eyes (31%) in six patients showed no change in VA with decreased CFZ thickness in 6/8 eyes with improved MCS. Genetic testing showed mutations of NR2E3, XLRS, CRB1, GPR98 and CNGB1. Conclusion: Non-leaking MCS occur in a variety of retinal dystrophies. Therapy with topical or systemic CAI has variable efficacy and may result in VA improvement with or without qualitative improvement in MCS and CFZ thickness.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalOphthalmic Genetics
DOIs
Publication statusAccepted/In press - Feb 21 2016

Fingerprint

Retinal Dystrophies
Visual Acuity
Carbonic Anhydrase Inhibitors
Genetic Testing
Optical Coherence Tomography
Therapeutics
Retrospective Studies
Regression Analysis

Keywords

  • Carbonic anhydrase inhibitor
  • macular cysts
  • retinal dystrophy

ASJC Scopus subject areas

  • Ophthalmology
  • Pediatrics, Perinatology, and Child Health
  • Genetics(clinical)

Cite this

Macular cystoid spaces in patients with retinal dystrophy. / Lingao, Michelle D.; Ganesh, Anuradha; Karthikeyan, Arcot S.; Zuhaibi, Sana Al; Al-Hosni, Amna; Khayat, Aisha Al; Capasso, Jenina; Trumler, Anya A.; Stroh, Eliza; Shekaili, Hilal Al; Cater, Jacqueline R.; Levin, Alex V.

In: Ophthalmic Genetics, 21.02.2016, p. 1-7.

Research output: Contribution to journalArticle

Lingao, MD, Ganesh, A, Karthikeyan, AS, Zuhaibi, SA, Al-Hosni, A, Khayat, AA, Capasso, J, Trumler, AA, Stroh, E, Shekaili, HA, Cater, JR & Levin, AV 2016, 'Macular cystoid spaces in patients with retinal dystrophy', Ophthalmic Genetics, pp. 1-7. https://doi.org/10.3109/13816810.2015.1101775
Lingao, Michelle D. ; Ganesh, Anuradha ; Karthikeyan, Arcot S. ; Zuhaibi, Sana Al ; Al-Hosni, Amna ; Khayat, Aisha Al ; Capasso, Jenina ; Trumler, Anya A. ; Stroh, Eliza ; Shekaili, Hilal Al ; Cater, Jacqueline R. ; Levin, Alex V. / Macular cystoid spaces in patients with retinal dystrophy. In: Ophthalmic Genetics. 2016 ; pp. 1-7.
@article{1fca6fc059a34a1283d3b3c03f6046e6,
title = "Macular cystoid spaces in patients with retinal dystrophy",
abstract = "Background: Non leaking macular cystoid spaces (MCS) are seen in some retinal dystrophies. Carbonic anhydrase inhibitor (CAI) treatment may reduce the size of MSC and improve vision. Methods: A retrospective study of patients with retinal dystrophy with MCS seen between 2009 and 2013 at two sites. Patients had ophthalmic examination, optical coherence tomography (OCT) and genetic testing. Patients with vision worse than 20/30 were treated with CAI. Post treatment visual acuity (VA), central foveal zone (CFZ) thickness, and qualitative estimation of MCS size were assessed. Results: Eighteen patients, 6–47 years old, were included. IVFA was performed in 15 (83{\%}) patients. Of the 26 eyes in 13 patients who were treated and followed, VA improved in 15 eyes (58{\%}) of 10 patients. Ten of these 15 eyes had decreased CFZ thickness and 9/10 showed qualitative MCS improvement. Regression analysis showed that change in CFZ thickness was not significantly predictive of change in final visual acuity (p = 0.405). Five of 15 eyes with improved VA had paradoxically increased CFZ thickness and 2/5 had enlarged MCS. Three of the treated eyes (11{\%}) in two patients had decreased VA with decreased CFZ thickness and improved MCS in 2/3 eyes. Eight eyes (31{\%}) in six patients showed no change in VA with decreased CFZ thickness in 6/8 eyes with improved MCS. Genetic testing showed mutations of NR2E3, XLRS, CRB1, GPR98 and CNGB1. Conclusion: Non-leaking MCS occur in a variety of retinal dystrophies. Therapy with topical or systemic CAI has variable efficacy and may result in VA improvement with or without qualitative improvement in MCS and CFZ thickness.",
keywords = "Carbonic anhydrase inhibitor, macular cysts, retinal dystrophy",
author = "Lingao, {Michelle D.} and Anuradha Ganesh and Karthikeyan, {Arcot S.} and Zuhaibi, {Sana Al} and Amna Al-Hosni and Khayat, {Aisha Al} and Jenina Capasso and Trumler, {Anya A.} and Eliza Stroh and Shekaili, {Hilal Al} and Cater, {Jacqueline R.} and Levin, {Alex V.}",
year = "2016",
month = "2",
day = "21",
doi = "10.3109/13816810.2015.1101775",
language = "English",
pages = "1--7",
journal = "Ophthalmic Genetics",
issn = "1381-6810",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Macular cystoid spaces in patients with retinal dystrophy

AU - Lingao, Michelle D.

AU - Ganesh, Anuradha

AU - Karthikeyan, Arcot S.

AU - Zuhaibi, Sana Al

AU - Al-Hosni, Amna

AU - Khayat, Aisha Al

AU - Capasso, Jenina

AU - Trumler, Anya A.

AU - Stroh, Eliza

AU - Shekaili, Hilal Al

AU - Cater, Jacqueline R.

AU - Levin, Alex V.

PY - 2016/2/21

Y1 - 2016/2/21

N2 - Background: Non leaking macular cystoid spaces (MCS) are seen in some retinal dystrophies. Carbonic anhydrase inhibitor (CAI) treatment may reduce the size of MSC and improve vision. Methods: A retrospective study of patients with retinal dystrophy with MCS seen between 2009 and 2013 at two sites. Patients had ophthalmic examination, optical coherence tomography (OCT) and genetic testing. Patients with vision worse than 20/30 were treated with CAI. Post treatment visual acuity (VA), central foveal zone (CFZ) thickness, and qualitative estimation of MCS size were assessed. Results: Eighteen patients, 6–47 years old, were included. IVFA was performed in 15 (83%) patients. Of the 26 eyes in 13 patients who were treated and followed, VA improved in 15 eyes (58%) of 10 patients. Ten of these 15 eyes had decreased CFZ thickness and 9/10 showed qualitative MCS improvement. Regression analysis showed that change in CFZ thickness was not significantly predictive of change in final visual acuity (p = 0.405). Five of 15 eyes with improved VA had paradoxically increased CFZ thickness and 2/5 had enlarged MCS. Three of the treated eyes (11%) in two patients had decreased VA with decreased CFZ thickness and improved MCS in 2/3 eyes. Eight eyes (31%) in six patients showed no change in VA with decreased CFZ thickness in 6/8 eyes with improved MCS. Genetic testing showed mutations of NR2E3, XLRS, CRB1, GPR98 and CNGB1. Conclusion: Non-leaking MCS occur in a variety of retinal dystrophies. Therapy with topical or systemic CAI has variable efficacy and may result in VA improvement with or without qualitative improvement in MCS and CFZ thickness.

AB - Background: Non leaking macular cystoid spaces (MCS) are seen in some retinal dystrophies. Carbonic anhydrase inhibitor (CAI) treatment may reduce the size of MSC and improve vision. Methods: A retrospective study of patients with retinal dystrophy with MCS seen between 2009 and 2013 at two sites. Patients had ophthalmic examination, optical coherence tomography (OCT) and genetic testing. Patients with vision worse than 20/30 were treated with CAI. Post treatment visual acuity (VA), central foveal zone (CFZ) thickness, and qualitative estimation of MCS size were assessed. Results: Eighteen patients, 6–47 years old, were included. IVFA was performed in 15 (83%) patients. Of the 26 eyes in 13 patients who were treated and followed, VA improved in 15 eyes (58%) of 10 patients. Ten of these 15 eyes had decreased CFZ thickness and 9/10 showed qualitative MCS improvement. Regression analysis showed that change in CFZ thickness was not significantly predictive of change in final visual acuity (p = 0.405). Five of 15 eyes with improved VA had paradoxically increased CFZ thickness and 2/5 had enlarged MCS. Three of the treated eyes (11%) in two patients had decreased VA with decreased CFZ thickness and improved MCS in 2/3 eyes. Eight eyes (31%) in six patients showed no change in VA with decreased CFZ thickness in 6/8 eyes with improved MCS. Genetic testing showed mutations of NR2E3, XLRS, CRB1, GPR98 and CNGB1. Conclusion: Non-leaking MCS occur in a variety of retinal dystrophies. Therapy with topical or systemic CAI has variable efficacy and may result in VA improvement with or without qualitative improvement in MCS and CFZ thickness.

KW - Carbonic anhydrase inhibitor

KW - macular cysts

KW - retinal dystrophy

UR - http://www.scopus.com/inward/record.url?scp=84958769811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958769811&partnerID=8YFLogxK

U2 - 10.3109/13816810.2015.1101775

DO - 10.3109/13816810.2015.1101775

M3 - Article

SP - 1

EP - 7

JO - Ophthalmic Genetics

JF - Ophthalmic Genetics

SN - 1381-6810

ER -